These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29129444)

  • 1. Biomarkers for subtypes of pancreatic ductal adenocarcinoma.
    Venkatesan P
    Lancet Oncol; 2017 Dec; 18(12):e718. PubMed ID: 29129444
    [No Abstract]   [Full Text] [Related]  

  • 2. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response.
    Muckenhuber A; Berger AK; Schlitter AM; Steiger K; Konukiewitz B; Trumpp A; Eils R; Werner J; Friess H; Esposito I; Klöppel G; Ceyhan GO; Jesinghaus M; Denkert C; Bahra M; Stenzinger A; Sprick MR; Jäger D; Springfeld C; Weichert W
    Clin Cancer Res; 2018 Jan; 24(2):351-359. PubMed ID: 29101303
    [No Abstract]   [Full Text] [Related]  

  • 3. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.
    Noll EM; Eisen C; Stenzinger A; Espinet E; Muckenhuber A; Klein C; Vogel V; Klaus B; Nadler W; Rösli C; Lutz C; Kulke M; Engelhardt J; Zickgraf FM; Espinosa O; Schlesner M; Jiang X; Kopp-Schneider A; Neuhaus P; Bahra M; Sinn BV; Eils R; Giese NA; Hackert T; Strobel O; Werner J; Büchler MW; Weichert W; Trumpp A; Sprick MR
    Nat Med; 2016 Mar; 22(3):278-87. PubMed ID: 26855150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy.
    Kaissis G; Ziegelmayer S; Lohöfer F; Steiger K; Algül H; Muckenhuber A; Yen HY; Rummeny E; Friess H; Schmid R; Weichert W; Siveke JT; Braren R
    PLoS One; 2019; 14(10):e0218642. PubMed ID: 31577805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRT81 and HNF1A expression in pancreatic ductal adenocarcinoma: investigation of predictive and prognostic value of immunohistochemistry-based subtyping.
    Rao J; Sinn M; Pelzer U; Riess H; Oettle H; Demir IE; Friess H; Jäger C; Steiger K; Muckenhuber A
    J Pathol Clin Res; 2024 May; 10(3):e12377. PubMed ID: 38750616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High nuclear Survivin expression as a poor prognostic marker in pancreatic ductal adenocarcinoma.
    Zhou L; Lu J; Liang ZY; Zhou WX; Yuan D; Li BQ; You L; Guo JC; Zhao YP
    J Surg Oncol; 2018 Dec; 118(7):1115-1121. PubMed ID: 30261114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma.
    Alemi F; Alseidi A; Scott Helton W; Rocha FG
    Curr Probl Surg; 2015 Sep; 52(9):362-98. PubMed ID: 26363649
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
    Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
    Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.
    Diana A; Wang LM; D'Costa Z; Azad A; Silva MA; Soonawalla Z; Allen P; Liu S; McKenna WG; Muschel RJ; Fokas E
    Oncotarget; 2016 Nov; 7(45):72819-72832. PubMed ID: 27637082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study.
    Guo JC; Zhang P; Zhou L; You L; Liu QF; Zhang ZG; Sun B; Liang ZY; Lu J; Yuan D; Tan AD; Sun J; Liao Q; Dai MH; Xiao GG; Li S; Zhang TP
    EBioMedicine; 2020 May; 55():102767. PubMed ID: 32361251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of lymph node positivity in treatment planning for early stage pancreatic cancer.
    Tran Cao HS; Zhang Q; Sada YH; Silberfein EJ; Hsu C; Van Buren G; Chai C; Katz MHG; Fisher WE; Massarweh NN
    Surgery; 2017 Sep; 162(3):557-567. PubMed ID: 28666686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of CX3CL1/CX3CR1 axis predicts a poor prognosis of pancreatic ductal adenocarcinoma.
    Xu X; Wang Y; Chen J; Ma H; Shao Z; Chen H; Jin G
    J Gastrointest Surg; 2012 Aug; 16(8):1493-8. PubMed ID: 22639377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Loehrer AP; Kinnier CV; Ferrone CR
    Adv Surg; 2016 Sep; 50(1):115-28. PubMed ID: 27520867
    [No Abstract]   [Full Text] [Related]  

  • 15. Metastatic Pancreatic Cancer.
    Hogendorf P; Durczyński A; Strzelczyk J
    J Invest Surg; 2018 Apr; 31(2):151-152. PubMed ID: 28267398
    [No Abstract]   [Full Text] [Related]  

  • 16. PGP9.5 as a prognostic factor in pancreatic cancer.
    Tezel E; Hibi K; Nagasaka T; Nakao A
    Clin Cancer Res; 2000 Dec; 6(12):4764-7. PubMed ID: 11156232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic factors for long-term survival in patients with pancreatic ductal adenocarcinoma].
    Kawaida H; Fujii H
    Nihon Rinsho; 2015 Mar; 73 Suppl 3():181-5. PubMed ID: 25857011
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.
    Knudsen ES; O'Reilly EM; Brody JR; Witkiewicz AK
    Gastroenterology; 2016 Jan; 150(1):48-63. PubMed ID: 26385075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
    Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
    Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma.
    Kneuertz PJ; Patel SH; Chu CK; Maithel SK; Sarmiento JM; Delman KA; Staley CA; Kooby DA
    Ann Surg Oncol; 2011 May; 18(5):1327-34. PubMed ID: 21369744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.